Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + BIIB022
- Development stage
- Discontinued
- Lead developer
- Biogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**sorafenib + BIIB022** is an investigational drug combination consisting of sorafenib, a small molecule multikinase inhibitor, and BIIB022, a non-glycosylated human IgG4 monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R). Sorafenib inhibits several kinases involved in tumor cell proliferation and angiogenesis, notably RAF kinase, VEGF receptors, and PDGF receptor. BIIB022 binds IGF-1R via an allosteric mechanism, blocking signaling without Fc-mediated effector functions, and is believed to inhibit IGF-1R-driven survival and proliferation in cancer cells. The combination was tested in advanced hepatocellular carcinoma but was found not to be tolerable due to dose limiting toxicity at the lowest planned dose[3].
- Brand names
- Nexavar
- Other names
- sorafenib tosylateBIIB-022BIIB022BIIB 022
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on sorafenib + BIIB022.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + BIIB022.